284 related articles for article (PubMed ID: 32716685)
1. PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
Wang AZ; O’Conno LP; Yerram NK; Long L; Zeng J; Mehralivand S; Harmon SA; Lebastchi AH; Ahdoot M; Gomella PT; Gurram S; Choyke PL; Merino MJ; Shih JH; Wood BJ; Turkbey B; Pinto PA
J Urol; 2020 Dec; 204(6):1229-1235. PubMed ID: 32716685
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer.
Lonergan PE; Washington SL; Cowan JE; Zhao S; Nguyen HG; Shinohara K; Cooperberg MR; Carroll PR
J Urol; 2020 Dec; 204(6):1216-1221. PubMed ID: 32519915
[TBL] [Abstract][Full Text] [Related]
3. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer.
Maggi M; Cowan JE; Fasulo V; Washington SL; Lonergan PE; Sciarra A; Nguyen HG; Carroll PR
J Urol; 2020 Dec; 204(6):1222-1228. PubMed ID: 33157570
[TBL] [Abstract][Full Text] [Related]
4. The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy.
Williams C; Khondakar NR; Daneshvar MA; O'Connor LP; Gomella PT; Mehralivand S; Yerram NK; Egan J; Gurram S; Rompré-Brodeur A; Webster BR; Owens-Walton J; Parnes H; Merino MJ; Wood BJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2021 Nov; 206(5):1157-1165. PubMed ID: 34181465
[TBL] [Abstract][Full Text] [Related]
5. Utility of Multiparametric Magnetic Resonance Imaging With PI-RADS, Version 2, in Patients With Prostate Cancer Eligible for Active Surveillance: Which Radiologic Characteristics Can Predict Unfavorable Disease?
Kim H; Pak S; Park KJ; Kim MH; Kim JK; Kim M; You D; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2020 Feb; 18(1):50-55. PubMed ID: 31640913
[TBL] [Abstract][Full Text] [Related]
6. Does the Visibility of Grade Group 1 Prostate Cancer on Baseline Multiparametric Magnetic Resonance Imaging Impact Clinical Outcomes?
Deniffel D; Salinas E; Ientilucci M; Evans AJ; Fleshner N; Ghai S; Hamilton R; Roberts A; Toi A; van der Kwast T; Zlotta A; Finelli A; Haider MA; Perlis N
J Urol; 2020 Dec; 204(6):1187-1194. PubMed ID: 32496160
[TBL] [Abstract][Full Text] [Related]
7. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
8. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide?
Chu CE; Cowan JE; Fasulo V; Washington SL; de la Calle C; Shoemaker J; Carroll PR
J Urol; 2021 Jan; 205(1):109-114. PubMed ID: 33198555
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Study of the Clinical Utility of Nontargeted Systematic Transperineal Prostate Biopsies in Patients Undergoing Pre-Biopsy Multiparametric Magnetic Resonance Imaging.
Connor MJ; Eldred-Evans D; van Son M; Hosking-Jervis F; Bertoncelli Tanaka M; Reddy D; Bass EJ; Powell L; Ahmad S; Pegers E; Joshi S; Sri D; Wong K; Tam H; Hrouda D; Qazi H; Gordon S; Winkler M; Ahmed HU
J Urol; 2020 Dec; 204(6):1195-1201. PubMed ID: 32516029
[TBL] [Abstract][Full Text] [Related]
10. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
11. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
Chu CE; Cowan JE; Lonergan PE; Washington SL; Fasulo V; de la Calle CM; Shinohara K; Westphalen AC; Carroll PR
Eur Urol Oncol; 2022 Oct; 5(5):537-543. PubMed ID: 33483265
[TBL] [Abstract][Full Text] [Related]
13. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
[TBL] [Abstract][Full Text] [Related]
14. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
15. The Association of Periprostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance.
Gregg JR; Surasi DS; Childs A; Moll N; Ward JF; Kim J; Daniel CR; Logothetis C; Bathala T; Davis JW
J Urol; 2021 Jan; 205(1):122-128. PubMed ID: 32718204
[TBL] [Abstract][Full Text] [Related]
16. Risk of Prostate Cancer after a Negative Magnetic Resonance Imaging Guided Biopsy.
Kinnaird A; Sharma V; Chuang R; Priester A; Tran E; Barsa DE; Delfin M; Kwan L; Sisk A; Felker E; Marks LS
J Urol; 2020 Dec; 204(6):1180-1186. PubMed ID: 32614257
[TBL] [Abstract][Full Text] [Related]
17. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
18. The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance.
Yaguchi G; Tang HJ; Deebajah M; Keeley J; Pantelic M; Williamson S; Gupta N; Peabody JO; Menon M; Dabaja A; Alanee S
Urol Oncol; 2020 Jun; 38(6):599.e9-599.e13. PubMed ID: 32265090
[TBL] [Abstract][Full Text] [Related]
19. Risk Stratification of Prostate Cancer According to PI-RADS® Version 2 Categories: Meta-Analysis for Prospective Studies.
Park KJ; Choi SH; Lee JS; Kim JK; Kim MH; Jeong IG
J Urol; 2020 Dec; 204(6):1141-1149. PubMed ID: 32716687
[TBL] [Abstract][Full Text] [Related]
20. Effects of "real life" prostate MRI inter-observer variability on total needle samples and indication for biopsy.
Rosenzweig B; Laitman Y; Zilberman DE; Raz O; Ramon J; Dotan ZA; Portnoy O
Urol Oncol; 2020 Oct; 38(10):793.e13-793.e18. PubMed ID: 32303407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
